1-20 of 191 results for subject:"Armed forces"
Librarians' tools
- Search time
- 0.271 seconds
- Solr query time
- 0.017 seconds
- Search query
- subject:"Armed forces"
- We searched for
- subject_t:"Armed forces" OR subject_t:"Military forces" OR subject_ses:90249
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask Her Majesty's Government, further to the Written Answer by Baroness Blackwood of North Oxford on 10 July (HL16834), what steps the Ministry of Defence has taken to address the concerns of the European Medicines Agency Pharmacovigilance Assessment Committee 2014 report on the toxicity of mefloquine (Lariam); and if they...
To ask Her Majesty's Government, further to the Written Answer by Baroness Blackwood of North Oxford on 10 July (HL16834), what steps the Ministry of Defence has taken to address the concerns of the European Medicines Agency Pharmacovigilance Assessment Committee 2014 report on the toxicity of mefloquine (Lariam); and if they...
Anti-malarial drugs are prescribed to Service personnel with the UK product information leaflet. For mefloquine, this reflects the recommendations of the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency.
All anti-malarial drugs have contraindications and a side effect profile which can be found in the British National Formulary or online at the Electronic Medicines Compendium. It is Ministry of Defence policy that healthcare professionals undertake a health risk assessment and to warn patients of the possible side effects of any anti-malarial drug.
To ask Her Majesty's Government when they intend to publish the results of the research into the side effects of malaria chemo-prophylaxis referred to in their second and third six-monthly progress updates to the House of Commons Defence Committee on its report An acceptable risk? The use of Lariam for...
To ask Her Majesty's Government when they intend to publish the results of the research into the side effects of malaria chemo-prophylaxis referred to in their second and third six-monthly progress updates to the House of Commons Defence Committee on its report An acceptable risk? The use of Lariam for...
Data collection for this research has been completed and data cleansing, analysis and production of a report is under way, with completion anticipated in 2019.
To ask Her Majesty's Government whether they intend that an addendum should be added to the Defence Mental Health and Wellbeing Strategy Report 2017–2022 in order to address the effects of neurotoxicity from mefloquine; if so, when it will be published; and if not, why not.
To ask Her Majesty's Government whether they intend that an addendum should be added to the Defence Mental Health and Wellbeing Strategy Report 2017–2022 in order to address the effects of neurotoxicity from mefloquine; if so, when it will be published; and if not, why not.
Mefloquine is effective in the prevention and treatment of malaria and is licensed for use by the Medicines and Healthcare products Regulatory Agency, which regulates medication in the UK. Bodies such as the Advisory Committee on Malaria Prevention, the World Health Organization and the United States Centers for Disease Control and Prevention continue to include mefloquine as an option for malaria chemoprophylaxis.
The current product information for mefloquine states that neuropsychiatric adverse reactions may occur during treatment and includes warnings and precautions to minimise these risks. It also states that such adverse reactions may persist for months, or longer, even after discontinuation of the drug. It has not been established, however, that such adverse reactions may be permanent.
For these reasons, there are no plans to add an addendum to the Defence Mental Health and Wellbeing Strategy Report 2017-2022.
To ask Her Majesty's Government whether the Surgeon General of Her Majesty’s Armed Forces recognises the chronic neurotoxic effects on members of the Armed Forces and Veterans from the administration of mefloquine (Lariam); and whether they will be addressing the problems caused by those effects in the near future.
To ask Her Majesty's Government whether the Surgeon General of Her Majesty’s Armed Forces recognises the chronic neurotoxic effects on members of the Armed Forces and Veterans from the administration of mefloquine (Lariam); and whether they will be addressing the problems caused by those effects in the near future.
Mefloquine is effective in the prevention and treatment of malaria and is licensed for use by the Medicines and Healthcare products Regulatory Agency, which regulates medication in the UK. Bodies such as the Advisory Committee on Malaria Prevention, the World Health Organization and the United States Centers for Disease Control and Prevention continue to include mefloquine as an option for malaria chemoprophylaxis.
The current product information for mefloquine states that neuropsychiatric adverse reactions may occur during treatment and includes warnings and precautions to minimise these risks. It also states that such adverse reactions may persist for months, or longer, even after discontinuation of the drug. It has not been established, however, that such adverse reactions may be permanent.
For these reasons, there are no plans to add an addendum to the Defence Mental Health and Wellbeing Strategy Report 2017-2022.
To ask Her Majesty's Government, further to the Written Answers by Lord O'Shaughnessy on 5 December (HL3532) and 27 November (HL3227), whether they have seen the unclassified order of the US Surgeon General’s Office of the Army Special Command of 13 September 2013; whether there is any difference between the drug...
To ask Her Majesty's Government, further to the Written Answers by Lord O'Shaughnessy on 5 December (HL3532) and 27 November (HL3227), whether they have seen the unclassified order of the US Surgeon General’s Office of the Army Special Command of 13 September 2013; whether there is any difference between the drug...
We have considered this order.
There is no difference in the anti-malarial drug Mefloquine (under the brand name Lariam) currently provided to the United Kingdom and United States armed forces.
Mefloquine is effective in the prevention and treatment of malaria. Approved by the Medicines and Health products Regulatory Agency, the current product information states that neuropsychiatric adverse reactions may occur during treatment and includes warnings and precautions to minimise these risks. Some of these reactions may persist, but it has not been established whether these are permanent.
Mefloquine continues to be recommended as a safe and effective form of malaria prevention by the Advisory Committee on Malaria Prevention, the World Health Organization and other respected organisations who take account of the body of global evidence.
To ask Her Majesty's Government what steps they have taken to ensure that the medical histories of all military personnel are accurate and complete and that Post Traumatic Stress Disorder is accurately diagnosed.
To ask Her Majesty's Government what steps they have taken to ensure that the medical histories of all military personnel are accurate and complete and that Post Traumatic Stress Disorder is accurately diagnosed.
Under national medical and professional body regulations and guidelines, there is a duty on health professionals to maintain accurate and comprehensive records. The Ministry of Defence (MOD) has a number of governance and other processes to ensure the accuracy and quality of the medical records of serving Armed Forces personnel. On discharge from Service, an individual's medical record is routinely checked before their care is passed to the NHS or equivalent primary healthcare services.
Every effort is made to correctly identify Armed Forces personnel with Post-Traumatic Stress Disorder (PTSD). When PTSD symptoms are recognised by a Defence Primary Care clinician it triggers a referral to an MOD Department of Community Mental Health. An assessment is then conducted by a nurse, psychiatrist or psychologist. The diagnosis of PTSD can only be confirmed by a consultant psychiatrist or psychologist and a nurse will request their review of the case to confirm the diagnosis.
To ask Her Majesty's Government what assessment they have made of neurotoxicity resulting from the administration of mefloquine to military personnel; and what steps they have taken to ensure that veterans suffering from mental health problems are not given drugs that may exacerbate their illness due to a reaction with...
To ask Her Majesty's Government what assessment they have made of neurotoxicity resulting from the administration of mefloquine to military personnel; and what steps they have taken to ensure that veterans suffering from mental health problems are not given drugs that may exacerbate their illness due to a reaction with...
There is no established evidence of prophylactic drugs having long-term side effects causing mental health issues.
The Royal College of Psychiatrists' 'Good Psychiatric Practice' report states clinicians must "be competent in obtaining a full and relevant history that incorporates developmental, psychological, social, cultural and physical factors". This includes the consideration and assessment of the effect of medication and the circumstances in which it is being prescribed.
My Lords, I understand that there is a second generation sort of biofuel that does not use food and food products but is generated from bacteria, using waste materials. How much of this biofuel is used in Ministry of Defence operations?
My Lords, I understand that there is a second generation sort of biofuel that does not use food and food products but is generated from bacteria, using waste materials. How much of this biofuel is used in Ministry of Defence operations?
My Lords, I cannot answer that question but I refer to a Question asked by the noble Baroness, Lady Worthington, last year. When the noble Lord, Lord Soley, asked a supplementary question about this, my noble friend replied that these are termed “advanced biofuels”, which I think relates to the question of the noble Countess. They,
“do not have a land-take impact—certainly not in terms of taking land out of agricultural use or requiring a reduction in rainforest. Moreover, they do not have an impact on food production. Consideration is being given to greater incentives for the production of advanced biofuels”.—[Official Report, 27/3/13; col. 1077.]
To ask Her Majesty’s Government what protection exists for continuity of employment, pension and service rights for members of the Territorial Army and reservists who are required to present their P45 forms when called upon for military duty, in view of the fact that a request for a P45 from...
To ask Her Majesty’s Government what protection exists for continuity of employment, pension and service rights for members of the Territorial Army and reservists who are required to present their P45 forms when called upon for military duty, in view of the fact that a request for a P45 from...
The Government take the continuity of employment and pension and service rights of members of the Territorial Army and other reservists as a matter of great importance. That is why they are provided with legal protection of their civilian employment through the Reserve Forces safeguard of the Employment Act 1985.
This gives the reservist the right to be reinstated in the same job in which they were employed before they were mobilised or, if it is not reasonable and practicable, to be re-employed by their civilian employer in the most favourable job and on the most favourable terms and conditions to the reservist.
Regarding the protection of pensions, reservists are eligible to become an active member of the Reserve Forces pension scheme (RFPS) when mobilised under the Reserve Forces Act 1996 or a corresponding power in the Reserve Forces Act 1980. When at the mobilisation centre they make a choice and complete a declaration that they wish to have the period of permanent service counted under the RFPS, or to remain in any civilian occupational or personal pension scheme or to join the state second pension.
Members of the Reserve Forces are asked to report to the mobilisation centres with either a P60 or P45 (not solely a P45), whichever is relevant, to confirm their civilian earnings and, if required, their employment status. This document can also be used to assist in the administration of any financial assistance award that they or their employer may claim.
To ask Her Majesty’s Government, further to the Written Answer by Lord Astor of Hever on 30 November 2011 (WA 67), whether any part of the Ministry of Defence maintains records of sickness and injury amongst members of HM Armed Forces similar to NHS Read Codes; and, if so, whether...
To ask Her Majesty’s Government, further to the Written Answer by Lord Astor of Hever on 30 November 2011 (WA 67), whether any part of the Ministry of Defence maintains records of sickness and injury amongst members of HM Armed Forces similar to NHS Read Codes; and, if so, whether...
To ask Her Majesty's Government further to the Written Answer by Baroness Taylor of Bolton on 5 May (WA 103–4), what method was used for the disposal of unused NAPS tablets once the threat that would necessitate their use had ended; and how they were accounted for.
To ask Her Majesty's Government further to the Written Answer by Baroness Taylor of Bolton on 5 May (WA 103–4), what method was used for the disposal of unused NAPS tablets once the threat that would necessitate their use had ended; and how they were accounted for.
To ask Her Majesty's Government further to the Written Answer by Baroness Taylor of Bolton on 5 May (WA 103–4), on how many occasions countermeasures against chemical weapons were deemed necessary; and how many times operational commanders instructed troops to start and stop taking NAPS tablets between January and March...
To ask Her Majesty's Government further to the Written Answer by Baroness Taylor of Bolton on 5 May (WA 103–4), on how many occasions countermeasures against chemical weapons were deemed necessary; and how many times operational commanders instructed troops to start and stop taking NAPS tablets between January and March...
To ask Her Majesty's Government further to the Written Answer by Baroness Taylor of Bolton on 5 May (WA 103–4), whether there was any difference between the formulation of NAPS tablets issued to members of Her Majesty's Armed Forces in 1990–91 and 2003 and those issued to members of the...
To ask Her Majesty's Government further to the Written Answer by Baroness Taylor of Bolton on 5 May (WA 103–4), whether there was any difference between the formulation of NAPS tablets issued to members of Her Majesty's Armed Forces in 1990–91 and 2003 and those issued to members of the...
To ask Her Majesty's Government how many members of Her Majesty's armed forces on military duties in Iraq have been issued with Nerve Agent Pre-treatment Sets (pyridostigmine bromide) since the beginning of 2003; how many are recorded as having taken the tablets; under what circumstances they were taken; and what...
To ask Her Majesty's Government how many members of Her Majesty's armed forces on military duties in Iraq have been issued with Nerve Agent Pre-treatment Sets (pyridostigmine bromide) since the beginning of 2003; how many are recorded as having taken the tablets; under what circumstances they were taken; and what...
| Month | Strips supplied | Total tablets |
| January 2003 | 85,573 | 1,797,033 |
| February 2003 | 155,541 | 3,266,361 |
| March 2003 | 104,910 | 2,203,110 |
| Total | 346,024 | 7,266,504 |
asked Her Majesty's Government:How many ex-gratia pension payments under the attributable benefits for reservists scheme for veterans of the 1990-91 Gulf War remain outstanding.
asked Her Majesty's Government:How many ex-gratia pension payments under the attributable benefits for reservists scheme for veterans of the 1990-91 Gulf War remain outstanding.